MarketCap
Facebook
X
Telegram
Venus Concept Cost of Revenue | VERO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.5 M | 24.2 M | 33.5 M | 31.5 M | 26.6 M | 33.8 M | 23.3 M | 12.2 M | 10.4 M | 12.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.8 M | 10.4 M | 22.8 M |
Quarterly Cost of Revenue Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.96 M | 6.26 M | 4.89 M | - | 5.09 M | 4.73 M | 5.83 M | - | 5.43 M | 5.86 M | 6.83 M | - | 8.17 M | 8.22 M | 8.64 M | - | 7.26 M | 7.11 M | 7.36 M | - | 7.18 M | 5.1 M | 5.23 M | - | 7.39 M | 7.74 M | 6.52 M | - | 2.66 M | 2.51 M | 3.18 M | - | 2.47 M | 3.49 M | 3.09 M | - | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.64 M | 2.4 M | 5.56 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
1.86 B | $ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
110 M | $ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 16.08 | 0.75 % | $ 576 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
15.8 M | $ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
64.8 M | $ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
75.3 K | - | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
500 K | $ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
804 M | $ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
194 M | $ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
79.5 M | $ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
133 M | $ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
19.5 M | $ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
AxoGen
AXGN
|
57.9 M | $ 43.32 | 0.48 % | $ 1.99 B | USA |
 |
Align Technology
ALGN
|
1.32 B | $ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
31.3 M | $ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
49 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
50 M | - | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
12.7 B | $ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
41.7 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
95.4 M | - | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
14 M | $ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
25.8 M | $ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
6.33 M | $ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
256 M | $ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
72.7 M | $ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
768 M | $ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
4.7 M | $ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Quanterix Corporation
QTRX
|
73.9 M | $ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
197 M | - | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
12.8 M | $ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
290 M | $ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
1.97 B | $ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
59.1 M | - | - | $ 4.23 B | USA |